Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TARA IYENGAR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1922217660
CMS profile
41628
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,164.14

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,996.34 96
Long term medical supply or device loan $166.66 2
Education $1.14 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TARA IYENGAR

NPI 1922217660 · CMS profile ID 41628

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922217660?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TARA IYENGAR, NPI 1922217660, CMS profile ID 41628. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922217660?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). TARA IYENGAR, NPI 1922217660, CMS profile ID 41628. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922217660?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
TARA IYENGAR, NPI 1922217660, CMS profile ID 41628, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922217660?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $2,164.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–99 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PUMA BIOTECHNOLOGY, INC. $23.3506/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942299565 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.2705/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929812149 CMS
GENZYME CORPORATION $13.5805/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938929821 CMS
PFIZER INC. $14.4105/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949153649 CMS
Novartis Pharmaceuticals Corporation $83.3305/16/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893778637 CMS
Amgen Inc. $26.3305/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939243913 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.8005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929809099 CMS
GENZYME CORPORATION $22.3005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938929817 CMS
Incyte Corporation $13.8205/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943035873 CMS
Janssen Biotech, Inc. $21.5705/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885515643 CMS
Genentech USA, Inc. $25.4305/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950777777 CMS
Novartis Pharmaceuticals Corporation $16.8405/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893778609 CMS
Daiichi Sankyo Inc. $11.9005/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930845223 CMS
Janssen Biotech, Inc. $21.2404/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885515639 CMS
PFIZER INC. $18.3804/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949127215 CMS
PFIZER INC. $1.1404/28/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949425167 CMS
GENZYME CORPORATION $19.4004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938929813 CMS
Seagen Inc. $16.3004/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904106413 CMS
Novartis Pharmaceuticals Corporation $17.6904/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893778605 CMS
Karyopharm Therapeutics Inc. $32.8604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946530519 CMS
PFIZER INC. $12.4104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949123069 CMS
Amgen Inc. $27.2704/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939860401 CMS
Janssen Biotech, Inc. $1.7704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885516115 CMS
Janssen Biotech, Inc. $13.2904/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885516119 CMS
Karyopharm Therapeutics Inc. $32.3204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946530525 CMS
E.R. Squibb & Sons, L.L.C. $17.4003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932498301 CMS
Merck Sharp & Dohme LLC $24.6903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944342189 CMS
AVEO Pharmaceuticals, Inc. $17.1803/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950107521 CMS
Janssen Biotech, Inc. $31.9903/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885516131 CMS
Merck Sharp & Dohme LLC $17.0603/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944131301 CMS
ARRAY BIOPHARMA INC $17.7503/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949098887 CMS
PFIZER INC. $17.4303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949068979 CMS
ABBVIE INC. $28.9102/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892896309 CMS
Merck Sharp & Dohme LLC $16.6702/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944098543 CMS
Merck Sharp & Dohme LLC $19.1202/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944314179 CMS
Rigel Pharmaceuticals, Inc. $12.0302/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962270463 CMS
PFIZER INC. $13.0802/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949062197 CMS
Astellas Pharma US Inc $14.2202/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940122185 CMS
Novartis Pharmaceuticals Corporation $15.4602/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893778601 CMS
Regeneron Healthcare Solutions, Inc. $13.8902/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927213103 CMS
Janssen Biotech, Inc. $25.5002/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885516123 CMS
Janssen Biotech, Inc. $13.7801/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885516127 CMS
SERVIER PHARMACEUTICALS LLC $23.8201/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964207417 CMS
GENZYME CORPORATION $12.3901/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938929805 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.4701/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929809689 CMS
Helsinn Therapeutics (U.S.), Inc. $12.1801/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904589541 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.7501/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887543391 CMS
Merck Sharp & Dohme LLC $23.9701/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944064031 CMS
EUSA Pharma (US) LLC $24.7501/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964301127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $868.96 52
PY2020 $509.79 28
PY2021 $1,583.89 57
PY2022 $2,164.14 99
PY2023 $1,398.44 60
PY2024 $2,247.18 101
PY2025 $2,683.80 108

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,492,032.34 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,176.55 12/31/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228815719
Principal investigator 1 PFIZER INC. $107,958.35 12/27/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228816396
Principal investigator 1 PFIZER INC. $9,124.65 12/13/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228815425
Principal investigator 1 PFIZER INC. $95,501.00 12/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706767
Principal investigator 1 PFIZER INC. $91,680.90 12/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707047
Principal investigator 1 PFIZER INC. $67.50 12/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707884
Principal investigator 1 PFIZER INC. $15,221.25 11/26/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228818799
Principal investigator 1 PFIZER INC. $91,680.90 11/10/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706949
Principal investigator 1 PFIZER INC. $7,640.05 11/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706947
Principal investigator 1 PFIZER INC. $114,601.20 11/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707888
Principal investigator 1 PFIZER INC. $52.50 11/05/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707956
Principal investigator 1 PFIZER INC. $2,308.50 11/05/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228818793
Principal investigator 1 PFIZER INC. $15,482.79 10/31/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228824913
Principal investigator 1 PFIZER INC. $52.50 10/24/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706763
Principal investigator 1 PFIZER INC. $133,701.40 10/21/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706765
Principal investigator 1 PFIZER INC. $15.00 10/21/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706945
Principal investigator 1 PFIZER INC. $83,241.34 10/09/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228824292
Principal investigator 1 PFIZER INC. $15.00 10/03/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707586
Principal investigator 1 PFIZER INC. $57,300.60 10/03/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707886
Principal investigator 1 PFIZER INC. $133,701.40 09/29/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706869
Principal investigator 1 PFIZER INC. $30.00 09/29/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707882
Principal investigator 1 PFIZER INC. $19,854.45 09/24/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228838014
Principal investigator 1 PFIZER INC. $2,756.70 09/09/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228837313
Principal investigator 1 PFIZER INC. $15,008.80 08/29/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228842051
Principal investigator 1 PFIZER INC. $210,102.20 08/25/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706769
Principal investigator 1 PFIZER INC. $45.00 08/25/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708064
Principal investigator 1 PFIZER INC. $38,200.40 08/15/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706871
Principal investigator 1 PFIZER INC. $22.50 08/08/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708062
Principal investigator 1 PFIZER INC. $2,857.95 07/31/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228847793
Principal investigator 1 PFIZER INC. $15.00 07/25/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228707411
Principal investigator 1 PFIZER INC. $2,424.60 07/16/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228846947
Principal investigator 1 PFIZER INC. $15.00 07/08/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228706943
Principal investigator 1 PFIZER INC. $6,388.20 06/26/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228851623
Principal investigator 1 PFIZER INC. $57,300.60 05/27/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840739
Principal investigator 1 PFIZER INC. $91,680.90 05/21/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840758
Principal investigator 1 PFIZER INC. $7.50 05/21/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840765
Principal investigator 1 PFIZER INC. $12,247.56 05/21/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840780
Principal investigator 1 PFIZER INC. $15.00 05/19/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840661
Principal investigator 1 PFIZER INC. $57,300.60 05/19/2025 Non-covered Recipient Entity
Ironwood Cancer Research Centers
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228840771
Principal investigator 1 PFIZER INC. $13,236.00 03/26/2025 Non-covered Recipient Entity
Ironwood Physicians PC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228862570